Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mora, J. S.
Right arrow Articles by Georgiades, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mora, J. S.
Right arrow Articles by Georgiades, J. A.
NEUROLOGY 1986;36:1137
© 1986 American Academy of Neurology

Intrathecal administration of natural human nterferon alpha in amyotrophic lateral sclerosis

Jesus S. Mora, MD, Theodore L. Munsat, MD, Ko-Pei Kao, MD, Lorenz J. Finison, PhD, Winifred Hedlund, RPT, Guy A. Bradley, BA, Richard Scheife, PhD and Jerzy A. Georgiades, MD, PhD

Neuromuscular Research Unit, Department of Neurology (Drs. Mora, Munsat, Kao, and Finison, Ms. Hedlund, Mr. Bradley, and Dr. Scheife), Tufts- New England Medical Center, Boston, MA; and the Immuno Modulators Laboratories, Inc. (Dr. Georgiades), Stafford, TX.

Ten patients with amyotrophic lateral sclerosis were given intrathecal injections of natural interferon alpha, 1 million units weekly for 7 to 24 weeks. Six patients completed the trial. Four voluntarily withdrew after 7 to 13 injections. The slopes of deterioration for 40 quantitative tests of neuromuscular function for the control and treatment periods were compared by paired t test in the six patients who completed the trial and in the patient who withdrew after 13 injections. No significant differences were found. The patients tolerated treatment well. The CSF reaction was modest and spontaneously reversible. Indomethacin and ibuprofen blocked interferon side effects.

Address correspondence and reprint requests to Dr. Munsat, Tufts University, Boston, MA 02111.

Supported by grants from the Muscular Dystrophy Association.

Accepted for publication December 18, 1985.




This article has been cited by other articles:


Home page
 NeurologyHome page
E. Beghi, A. Chio, M. Inghilleri, L. Mazzini, A. Micheli, G. Mora, M. Poloni, R. Riva, L. Serlenga, D. Testa, et al.
A randomized controlled trial of recombinant interferon beta-1a in ALS
Neurology, January 25, 2000; 54(2): 469 - 469.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
L. Jacobs and K. P. Johnson
A Brief History of the Use of Interferons as Treatment of Multiple Sclerosis
Arch Neurol, December 1, 1994; 51(12): 1245 - 1252.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
H. Mitsumoto, M. R. Hanson, and D. A. Chad
Amyotrophic Lateral Sclerosis: Recent Advances in Pathogenesis and Therapeutic Trials
Arch Neurol, February 1, 1988; 45(2): 189 - 202.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
L. Jacobs, A. M. Salazar, R. Herndon, P. A. Reese, A. Freeman, R. Jozefowicz, A. Cuetter, F. Husain, W. A. Smith, R. Ekes, et al.
Intrathecally Administered Natural Human Fibroblast Interferon Reduces Exacerbations of Multiple Sclerosis: Results of a Multicenter, Double-blinded Study
Arch Neurol, June 1, 1987; 44(6): 589 - 595.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by AAN Enterprises, Inc.